National Comprehensive Cancer Network
- Educational Events & Programs
- NCCN Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™
- NCCN Annual Congress: Hematologic Malignancies™
- Regional Guidelines in Oncology Symposia
- NCCN Guidelines Update Webinar Series™
- State-of-the-Art Approaches to the Treatment of NSCLC
- NCCN Academy for Excellence & Leadership in Oncology™
- NCCN Resource Tool: REMS
- NCCN CME/CE Programs
- NCCN Oncology Case Management Program™
- NCCN International Programs
About NCCN
NCCN Updates: Guidelines, Drugs & Biologics
Octreotide therapy for asymptomatic patients with recurrent, unresectable carcinoid tumors added to NCCN Clinical Practice Guidelines in Oncology™ for Neuroendocrine Tumors
The NCCN Clinical Practice Guidelines in Oncology™ for Neuroendocrine Tumors have been updated to include octreotide therapy as a new management option for asymptomatic patients with recurrent, unresectable carcinoid tumors as a category 2A recommendation. This addition is based on recently published interim results of a placebo controlled phase III trial (PROMID). View the NCCN Guidelines
NCCN Clinical Practice Guidelines in Oncology™ for Central Nervous System cancers updated
For patients with glioblastoma multiforme, adjuvant treatment decisions are now based on patient performance status. For recurrence/salvage therapy in glioblastoma multiforme, bevacizumab can now be used as a single agent without irinotecan. Previously, bevacizumab was an option only when used in combination with irinotecan. For anaplastic astrocytoma/anaplastic oligodendroglioma, an analogous update was made with regards to the use of bevacizumab as a single agent; it can now be used with or without irinotecan. View the NCCN Guidelines
NCCN Clinical Practice Guidelines in Oncology™ for Venous Thrombolytic Embolism updated
An option for use of graduated compression stockings (GCS) for patients without contraindications for anticoagulation treatment was added to the Guidelines for Inpatient Venous Thromboembolism Prophylaxis. GCS were also added as a treatment option for patients with a pelvic/iliac/IVC or femoral/popliteal DVT. View the NCCN Guidelines
Everolimus added to NCCN Clinical Practice Guidelines in Oncology™ for Kidney Cancer
On Monday, April 13, 2009, everolimus was added to the NCCN Clinical Practice Guidelines in Oncology™ for Kidney Cancer as a category 1 option for relapsed or unresectable stage IV disease in patients with predominant clear cell histology who have progressed on prior TKI therapy. View the NCCN Guidelines
E-mail
Print
Mark
|
|
|
|
|
|
|
||